Is NCT07599982 recruiting in Sandy City, UT?

Yes, NCT07599982 is currently recruiting participants at its Sandy City, UT location. This type 1 diabetes (t1d) clinical trial is actively enrolling qualified participants.

How do I join the type 1 diabetes (t1d) clinical trial in Sandy City?

To join this clinical trial in Sandy City, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Sandy City clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Type 1 Diabetes (T1D) Clinical Trial in Sandy City, UT

About This Type 1 Diabetes (T1D) Study in Sandy City

A 13-week multi-center single-arm trial, preceded by a 2-week standard therapy phase, will be conducted to assess the safety of MODI, an insulin titration algorithm, in adults with type 1 diabetes (T1D) who use multiple daily insulin injections (MDI), or with type 2 diabetes (T2D) who use MDI, basal insulin only, or who are candidates to initiate basal insulin, in conjunction with continuous glucose monitoring (CGM).

Sponsor: DreaMed Diabetes

Who Can Participate

Inclusion Criteria

Clinical diagnosis, based on investigator assessment, of T1D or T2D of at least 6 months duration at time of informed consent

Insulin therapy as follows:

If T1D, using MDI insulin therapy for at least 3 months prior to screening; willing to follow a mealtime insulin dosing approach during the study, using either (a) time-of-day-based dosing (breakfast, lunch, dinner) or (b) meal-size-based dosing (small, normal, large); and taking 1 basal insulin injection per day for at least 1 week prior to screening

If T2D, either: i. not using insulin in the 3 months prior to screening, but require initiation of a basal-only insulin regimen based on investigator assessment ii. using only basal insulin for at least 3 months prior to screening and taking 1 basal insulin injection per day for at least 1 week prior to screening iii. using MDI for at least 3 months prior to screening; willing to follow a mealtime insulin dosing approach during the study, using either (a) time-of-day-based dosing (breakfast, lunch, dinner) or (b) mealsize-based dosing (small, normal, large); and taking 1 basal insulin injection per day for at least 1 week prior to screening

Age at time of consent 18-80 years

HbA1c \>7.5% and \<12% as measured by point-of-care device or local lab at the time of screening

Using only injected insulin types that are specified in the MODI Instructions for Use materials

Stable doses of non-insulin glucose lowering medications over the 4 weeks preceding screening as determined by Investigator and no changes anticipated for the duration of the study, unless a dose reduction or discontinuation, as determined by Investigator, is indicated for safety reasons

Stable doses of weight loss medications that may have a meaningful effect on glycemic control over the 4 weeks preceding screening and no changes anticipated for the duration of the study, unless a dose reduction or discontinuation, as determined by Investigator, is indicated for safety reasons

Weight between 80 - 440 lb at the time of screening

Willing to use FSL 3 System according to manufacturer instructions and to avoid use of any other personal CGM system during the period of study participation

Willing to document insulin delivery, meals, and daily activities in the Diary mobile app

Has a smartphone compatible with study requirements: either iOS version 17.0 or higher, or Android version 10.0 or higher, and willing to install required apps and use them as instructed during the period of study participation, with internet connectivity for a data upload at least once per day.

Is deemed an appropriate candidate for automatic insulin guidance therapy per Investigator assessment

Investigator has confidence that the participant has the cognitive ability necessary for study participation, can successfully operate all study devices, and can adhere to the protocol

Has a sufficient understanding of written/spoken English for legally effective informed consent and successful use of the study mobile apps

If woman of childbearing potential, is willing and able to have pregnancy testing

Exclusion Criteria

Use of an insulin pump within 3 months prior to informed consent

Use of mixed insulin or intermediate insulin (NPH) within the past 3 months prior to screening

Taking more than 128 units of daily basal insulin or more than 79 units in a single bolus insulin injection in the 7 days prior to screening

Any medical condition which in the opinion of the investigator, would put the participant at an unacceptable safety risk, such as untreated malignancy, unstable cardiac disease, unstable or end-stage renal disease, and/or eating disorders (i.e. anorexia/bulimia)

Current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or angina that prevents moderate exercise despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the 12 months prior to screening

Any planned surgery during the study which could be considered major in the judgment of the investigator

History of more than 1 severe hypoglycemic event in the 6 months prior to screening

History of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic syndrome (HHS) in the 6 months prior to screening

Blood disorder or dyscrasia within 3 months prior to screening which in the investigator's opinion could interfere with determination of HbA1c

Any condition or intervention that may affect red blood cell turnover, in the 3 months prior to the study and during the study, such as blood transfusion or donation

Has taken oral or injectable corticosteroids within 2 weeks prior to screening or plans to take oral or injectable corticosteroids during the study

Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the Investigator's clinical judgment

Is an employee of DreaMed Diabetes, is a study Investigator or a member of the Investigator's study team, or is immediate family member (spouse, biological or legal guardian, child, sibling, parent) of any of the aforementioned

Participation in another clinical study using an investigational drug or device in the 90 days prior to screening or intends to participate during the study period

Pregnant or lactating, planning to become pregnant during the study, or is a woman of childbearing potential and not on acceptable form of birth control (acceptable includes abstinence, condoms, oral/injectable contraceptives, IUD, or implant); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months postmenopausal)

Unable to tolerate adhesive tape or has any unresolved skin condition that could impact the CGM sensor

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Sandy City?

Yes, this clinical trial (NCT07599982) has an active research site in Sandy City, UT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Type 1 Diabetes (T1D) Treatment Options in Sandy City, UT

If you're searching for type 1 diabetes (t1d) treatment options in Sandy City, UT, this clinical trial (NCT07599982) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Sandy City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced type 1 diabetes (t1d) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all type 1 diabetes (t1d) clinical trials near you to find additional studies recruiting in your area.

Type 1 Diabetes (T1D) Clinical Trial in Sandy City, UT

Expert Care in Sandy City

IRB Approved

No-Cost Care

Apply for This Sandy City Location

Why Participate?

Simple Process